Zogenix wins FDA nod for extended-release hydrocodone; UMass researchers jam up nanoparticles with long-term stability;

> Zogenix ($ZGNX) won FDA approval for its extended-release hydrocodone painkiller after a panel of experts said it wanted the administration to hold off. Story

> Researchers at the University of Massachusetts Amherst have kinetically trapped one liquid within another to be stable over a long period of time, a discovery that could have clear implications for drug delivery. More

> Phosphagenics ($PPGNY) welcomed positive Phase I results for its oxymorphone patch for pain management. Release

> Case Western Reserve University researchers accepted a grant from the National Science Foundation to make complex nanoparticles more easily reproducible for manufacturing. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.